Intratumoral or Subcutaneous MK-2118, a Non-Cyclic Dinucleotide STING Agonist, With or Without Pembrolizumab for Advanced or Metastatic Solid Tumors or Lymphomas

By sjmartinez • January 24, 2025

Luke JJ, Sweis RF, Hecht JR, Schneider R, Stein MN, Golan T, Yap TA, Khilnani A, Huang M, Zhao R, Jemielita T, Patel SP. Intratumoral or Subcutaneous MK-2118, a Non-Cyclic Dinucleotide STING Agonist, With or Without Pembrolizumab for Advanced or Metastatic Solid Tumors or Lymphomas. Clin Cancer Res. 2025 Jan 23. doi: 10.1158/1078-0432.CCR-24-2824. Epub ahead of print. PMID: 39846804.

Tags: Hematology/Oncology, Publications

Case of Relapsed, Metastatic Cutaneous Squamous Cell Carcinoma With HER2 Mutation Treated With Trastuzumab

Kye Y, Marshalek J, Wise D, Peng S, Hwang A. Case of Relapsed, Metastatic Cutaneous Squamous Cell Carcinoma With HER2 Mutation Treated With Trastuzumab. Clin[...]

Frontiers in Systemic Therapy for Unresectable or Metastatic Adrenocortical Carcinoma: Harnessing Novel Therapeutic Approaches

Singer AE, Kathuria-Prakash N, Shabsovich D, Garcia L, Damron L, Pantuck AJ, Drakaki A. Frontiers in Systemic Therapy for Unresectable or Metastatic Adrenocortical Carcinoma: Harnessing[...]

Impact of postoperative fluorodeoxyglucose positron emission tomography/computed tomography on adjuvant head and neck cancer treatment

Courtney PT, Juarez Casillas JE, Liu EY, Sim MS, Chau LW, Lopez-Chicas RE, St John MA, Abemayor E, Blackwell KE, Chhetri DK, Gopen QS, Kedeshian[...]